Search results
Showing 1531 to 1545 of 2183 results for guidelines
Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Obinutuzumab with mycophenolate mofetil for treating lupus nephritis (TA1131)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with mycophenolate mofetil for treating lupus nephritis in adults.
What is the optimal antibiotic prophylaxis regimen for women who are having a surgical abortion?
review the evidence this. A cross-reference has been included to the NICE guideline on preventing sexually transmitted infections and...
measurement of pulse, blood pressure and respiratory rate in line with the NICE guideline on sepsis . Hourly monitoring of temperature...
Evidence-based recommendations on QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography.
NICE has developed a medtech innovation briefing (MIB) on Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia .
NICE has developed a medtech innovation briefing (MIB) on moorLDLS-BI for burn depth assessment .
This guidance has been updated and replaced by NICE guideline CG178. This guideline updates and replaces NICE guideline CG1.
Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.
View recommendations for TA160Show all sections
Cabotegravir for preventing HIV-1 in adults and young people (TA1106)
Evidence-based recommendations on cabotegravir (Apretude) for preventing HIV-1 in adults and young people.
Can risk of contrast-induced acute kidney injury be stratified by eGFR thresholds?
factors were taken from recommendation 1.1.6 (developed as part of the 2013 guideline) apart from the level of eGFR which was based on...
Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy.
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
Immunisations: reducing differences in uptake in under 19s (PH21)
This guideline has been replaced by NICE guideline NG218.
Hyperglycaemia in acute coronary syndromes: management (CG130)
This guideline has been replaced by NICE guideline NG185.